AAA. K. Abdrakhmanova

A. K. Abdrakhmanova

*This is an algorithmically generated author record based on publicly available information.

A. K. Abdrakhmanova has a total of 520 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • OROPHARYNGEAL CARRIAGE OF NEISSERIA MENINGITIDIS AMONG STUDENTS AT ASFENDIYAROV KAZAKH NATIONAL MEDICAL UNIVERSITY, ALMATY, KAZAKHSTAN

    by M.A. Smagul, L.K. Kasabekova, A.S. Esmagambetova, G.T. Nukenova, A.M. Sataeva, A.S. Mutalieva, A.T. Kalykova, Zh. Soltanay, A.M. Sadykova, R.ZH. Baykhozhaeva, et al.

    Background. Invasive meningococcal disease (IMD) caused by Neisseria meningitidis remains a serious public health concern, particularly among unvaccinated young people living in organized settings such as student dormitories. Objective. The aim of the study was to assess the prevalence of Neisseria meningitidis carriage among students at the S.D.Asfendiyarov Kazakh National Medical University during the initial screening, to determine changes in carriage rates after 7–8 months, and to identify potential epidemiological risk factors. Materials and methods. An observational cross-sectional study was conducted among first-year students of Asfendiyarov Kazakh National Medical University. Examinations were performed at two time points: before moving into dormitories (Stage I) and after 7–8 months (Stage II). Oropharyngeal swabs were collected from 648 students at baseline and 617 at follow-up by trained laboratory staff. Detection of N. meningitidisand its serogroups was performed using PCR. Statistical analysis was carried out in STATA software. Associations between carriage and potential risk factors were assessed using X2 or Fisher’s exact tests, with statistical significance set at p < 0.05. Results. A total of 588 students (mean age 18 years) were included in the analysis. None of the carriers had clinical manifestations of disease. At Stage I, N. meningitidis carriage was detected in 18 students (3%). At Stage II, the carriage rate increased to 43 students (7%). At baseline, male sex (p = 0.011) and living with three or more roommates (p= 0.025) were significantly associated with carriage. Smoking status, frequency of visiting public places, and having a partner were not associated with meningococcal carriage. During follow-up, reported symptoms showed no statistically significant association with PCR-confirmed carriage. Conclusion. The prevalence of N. meningitidis carriage increased markedly during the first months of university attendance. These findings highlight the importance of implementing preventive measures in student populations to reduce the risk of IMD transmission. Введение. Инвазивная менингококковая инфекция (ИМИ), вызванная Neisseria meningitidis, остаётся серьёзной проблемой общественного здравоохранения, особенно среди невакцинированных молодых людей, проживающих в организованных коллективах, таких как студенческие общежития. Цель исследования. Оценить распространённость носительства Neisseria meningitidis среди студентов Казахского национального медицинского университета имени С.Д. Асфендиярова при первичном обследовании, определить изменение частоты носительства через 7–8 месяцев и выявить возможные эпидемиологические факторы риска. Материалы и методы.Проведено обсервационное кросс-секционное исследование среди студентов первого курса Казахского национального медицинского университета имени С. Асфендиярова. Обследование проводилось в две временные точки: до заселения в общежитие (I этап) и через 7–8 месяцев (II этап). Материалом исследования служили мазки из ротоглотки. Пробы были получены у 648 студентов на I этапе и у 617 — на II этапе. Выявление N. meningitidis и его серогрупп осуществлялось методом ПЦР. Статистический анализ выполнен с использованием программы STATA с применением критериев X2 и точного критерия Фишера; уровень значимости принят равным p <0,05. Результаты. В анализ включены данные 588 студентов со средним возрастом 18 лет. Клинические проявления ИМИ у носителей отсутствовали. На I этапе носительство N. meningitidis выявлено у 18 студентов (3%), на II этапе — у 43 (7%). Факторами, статистически значимо ассоциированными с носительством при первичном обследовании, были мужской пол (p= 0,011) и проживание с тремя и более соседями (p = 0,025). Курение, посещение общественных мест и наличие партнёра статистически значимой связи с носительством не имели. При повторном обследовании выявленные жалобы также не ассоциировались с носительством. Выводы. Частота носительства N. meningitidis существенно возрастает в первые месяцы обучения в вузе, что подчёркивает необходимость внедрения профилактических мероприятий в студенческой среде. Кіріспе. Neisseria meningitidis қоздырғышымен шақырылатын инвазивті менингококкты инфекция (ИМИ) қоғамдық денсаулық сақтау үшін өзекті мәселе болып...

  • Open Access

    Impact of vaccination status on the clinical course and outcomes of acute COVID-19 period: data from the international registry "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors" (AKTIV-4)

    by G Arutyunov, E Tarlovskaya, A Arutyunov, D Polyakov, Yu. Lopatin, A Chesnikova, L Balykova, A Vaisberg, A Galyavich, N Grigorieva, et al.

    Aim. To assess the effectiveness of vaccination against Omicron and Delta variants according to the international registry "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors" (AKTIV-4).Material and methods. The AKTIV-4 registry included men and women over 18 years of age with a diagnosis of coronavirus disease 2019 (COVID-19) (oropharyngeal and nasopharyngeal swabs, SARS-CoV-2 antibody titers, typical computed tomography performance), undergoing hospital treatment. A total of 3543 patients from 25 medical centers in 7 countries (the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan) were included in the AKTIV-4 registry.Results. The clinical status of patients from the AKTIV-4 registry was more severe than in the AKTIV-1 and AKTIV-2 registries. Patients in the AKTIV-4 registry were older than patients in the AKTIV-1 registry. The inhospital mortality rate in patients in the AKTIV-4 registry was higher (8,41%, pConclusion. Vaccination, primarily with Sputnik V, is an independent predictor of survival in hospitalized COVID-19 patients and reduces the risk of death by 62% according to multivariate analysis.

  • Open Access

    Clinical and laboratory characteristics of COVID-19 in hospitalized hypertensive patients

    by A. A. Abilbayeva, A. S. Tarabayeva, G. M. Idrisova, R. A. Yegemberdiyeva, A. K. Abdrakhmanova, A. M. Sadykova, A. K. Duisenova

    Objective. To identify clinical and laboratory differences of COVID-19 in patients with hypertension (HTN), as well as to identify factors associated with its severe course in these patients. Design and methods. A retrospective analysis of case histories of 940 patients with COVID-19 was performed. Statistical analysis was carried out by the method of contingency tables using Pearson's Chi-square test with Bonferroni correction, multiple logistic regression analysis and ROC-analysis were also applied. Results. The group of patients with COVID-19 and HTN showed a number of significant differences compared with the group of patients without HTN history. The study group was characterized by higher rates of females, people over 65, patients with severe COVID-19. They were more likely to have diabetes mellitus, coronary heart disease, and chronic kidney disease. On admission, in the group of HTN patients, leukocytosis and elevated blood glucose levels were more common, as well as pneumonia, shortness of breath and low saturation (p < 0,05). Multivariate logistic regression analysis showed that the presence of coronary heart disease (odds ratio (OR) = 3,492, 95 % confidential interval (CI): 2,016-6,048), leukocytosis (OR = 1,376, 95 % CI: 1,540-7,703), thrombocytopenia (OR = 1,779, 95 % CI: 1,031-3,071) and low SpO2 saturation (OR = 3,265, 95 % CI: 1,996-5,341) were associated with severe COVID-19 in hypertensive patients. ROC-analysis showed that the combination of the identified factors increases power of their association with the severe COVID-19 in HTN patients (AUC = 0,766). Conclusions. 1. Some indicators of hospitalized COVID-19 patients with HTN are different compared to patients with no HTN history. 2. Factors associated with severe COVID-19 in individuals with HTN do not differ from those in the general population of COVID-19 patients. 3. Severe COVID-19 in patients with HTN was strongly associated with the low SpO2 saturation and the presence of concomitant coronary heart disease.

  • Open Access

    Newly diagnosed diseases and the frequency of their occurrence in patients after a new coronavirus infection. Results of an International Register "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)" (12-month follow-up)

    by G P Arutyunov, E I Tarlovskaya, A G Arutyunov, D S Polyakov, Yu. N Belenkov, A O Konradi, Yu. M Lopatin, A P Rebrov, S N Tereshchenko, A I Chesnikova, et al.

    Aim. To analyze newly diagnosed diseases and features of the post-COVID course in patients after a coronavirus disease 2019 (COVID-19) within 12-month follow-up.Material and methods. A total of 9364 consecutively hospitalized patients were included in the ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to the ACTIV registry, 18,1% of patients after COVID-19 had newly diagnosed diseases (NDDs) over the next 12 months. Hypertension (HTN), type 2 diabetes and coronary artery disease (CAD) prevailed in the NDD structure. Comparison of the age-standardized incidence of NDDs (HTN, CAD, diabetes) in the post-COVID period in the ACTIV registry with NDD incidence in 2019 according to Rosstat and the expected incidence of NDDs according to the EPOHA study revealed that HTN, diabetes, CAD in patients after COVID-19 were registered more often as follows: HTN by 7,0 and 4,4 times, diabetes by 7,3 and 8,8 times, CAD by 2,3 and 2,9 times, respectively. NDDs most often developed in patients aged 47 to 70 years. Comparison of the actual and expected number of cases of newly diagnosed HTN, CAD and diabetes depending on age showed that the actual number of cases in the population of patients in the ACTIV register is significantly higher than expected for patients aged 45-69 years and for patients with hypertension or diabetes and aged Conclusion. Available evidence suggests that a strategy for managing COVID-19 survivors should include mandatory screening for early detection of cardiovascular disease and diabetes, which will be key to reducing the risk of further COVID-19 consequences.


  • Open Access

    The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries

    by A G Arutyunov, E I Tarlovskaya, G R Galstyan, T I Batluk, R A Bashkinov, G G Arutyunov, Yu N Belenkov, A O Konradi, Yu M Lopatin, A P Rebrov, et al.

    BACKGROUND. There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).AIM. To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.MATERIALS AND METHODS. AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected the data of hospitalized patients and included 3 visits. All subjects were divided into 3 groups: not overweight (n=2139), overweight (n=2931) and obese (n=2666).RESULTS. A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (pCONCLUSION. Overweight and/or obesity is a significant risk factor for severe course of the new coronavirus infection and the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.


  • Open Access

    Clinical and laboratory COVID-19 features in hospitalized patients with concomitant diabetes mellitus type 2: A retrospective study

    by Arailym Abilbayeva, Anel Tarabayeva, Gulzhana Idrisova, Aigul Abdrakhmanova, Ainur Sadykova, Ravilya Yegemberdiyeva, Amangul Duisenova

    Objective: To investigate the prevalence of diabetes mellitus in comorbidity structures and its effect on the clinical course in hospitalized COVID-19 patients in south region of Kazakhstan. Material and methods: A retrospective analysis of data from 918 patients with COVID-19 treated at the City Clinical Infectious Diseases Hospital was carried out. Pearson's Chi-square test and Student's t-test were conducted. Results: In Kazakhstan, diabetes mellitus occupies the second position in the structure of comorbidities in patients with COVID-19 with a share of 20%. Diabetes mellitus in patients most often occurs in combination with cardiovascular diseases and arterial hypertension (20.3% and 16.3%, respectively). Combination of diabetes mellitus, arterial hypertension and other diseases was detected in 72.4% of patients. Combination of diabetes mellitus, cardiovascular and other diseases was detected in 32.5%. In diabetes mellitus patients, COVID-19 was more severe, the hospital stay was longer, and patients over 60 years of age suffered. These patients had a combination of diabetes mellitus with arterial hypertension, obesity, and cardiovascular diseases. Hyperglycemia, elevated blood pressure, rapid breathing, and low saturation were more common for these patients. Conclusion: Diabetes mellitus ranks second in the structure of comorbidities in COVID-19 in the south region of Kazakhstan and is characterized by a combination with cardiovascular diseases, arterial hypertension and obesity. In patients with diabetes, COVID-19 is more severe, which affects the length of stay in the hospital, the mortality rate and the need for transfer to the Intensive Care Unit.


  • Open Access

    Clinical features of post-COVID period. Results of an International Register "Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)" (12-month follow-up)

    by G. P. Arutyunov, E. I Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, et al.

    Aim. To investigate on post-COVID period in patients of the Eurasian region.Material and methods. A total of 9364 consecutively hospitalized patients were included in ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to ACTIV register, 63% of patients after COVID-19 had new adverse symptoms or exacerbations of the existing symptoms lasting for up to 1 year. After hospital discharge, 79,8% of patients sought unscheduled medical attention in the first 3 months, 79,1% at 4-6 months, and 64,8% at 7-12 months. Readmission rate was 11,8% in the first 3 months, 10,9% at 4-6 months, and 10,1% at 7-12 months. The most common reasons for unscheduled treatment in the first 3 months were uncontrolled hypertension, decompensated type 2 diabetes, destabilization of coronary artery disease, gastrointestinal disease, AF episodes, exacerbation of asthma and chronic obstructive pulmonary disease, decompensated heart failure (HF). The 12-month mortality of COVID-19 survivors after the discharge was 3,08%. Multivariate analysis showed that independent risk factors for fatal outcome were age (direct correlation), the levels of hemoglobin (inverse correlation), oxygen saturation (inverse correlation), and aspartate aminotransferase (direct correlation), as well as class III-IV HF, prior stroke, cancer, inhospital acute kidney injury. Based on these identified risk factors, a nomogram was constructed to determine the 3-month mortality risk after discharge.Conclusion. Analysis of ACTIV register showed that end of the acute phase of COVID-19 does not imply a complete recovery.


  • Open Access

    Lipid profile in hospitalized patients with COVID-19 depending on the outcome of its acute phase: data from the international registry "Dynamics analysis of comorbidities in SARS-CoV-2 infection survivors"

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, G. G. Airapetyan, et al.

    Aim. To study the lipid profile in hospitalized patients with coronavirus disease 2019 (COVID-19) depending on the outcome of its acute phase according to the AKTIV international registry.Material and methods. The AKTIV registry included men and women over 18 years of age with a diagnosis of COVID-19, who were treated in a hospital. A total of 9364 patients were included in the registry, of which 623 patients were analyzed for levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides on days 1-2 of hospitalization. The level of high-density lipoprotein cholesterol (HDL-C) was calculated using the Friedewald equation.Results. We found that a decrease in LDL-C level was significantly associated with an unfavorable prognosis for hospitalized patients with COVID-19. This pattern persisted in both univariate and multivariate analyses. LDL-C levels in the final multivariate model had a significant relationship with the prognosis (an increase in the death risk by 1,7 times with a decrease per 1 mmol/l). In addition, we found that the survival of patients with an indicator level of Conclusion. A decrease in LDL-C in the acute period is significantly associated with an unfavorable prognosis for hospitalized patients with COVID-19. Determination of LDL-C can be included in the examination program for patients with COVID-19. However, the predictive value of this parameter requires further study in prospective clinical studies.


  • Open Access

    Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, et al.

    Aim.To study the clinical course specifics of coronavirus disease 2019 (COVID-19) and comorbid conditions in COVID-19 survivors 3, 6, 12 months after recovery in the Eurasian region according to the AKTIV register.Material and methods.The AKTIV register was created at the initiative of the Eurasian Association of Therapists. The AKTIV register is divided into 2 parts: AKTIV 1 and AKTIV 2. The AKTIV 1 register currently includes 6300 patients, while in AKTIV 2 — 2770. Patients diagnosed with COVID-19 receiving in- and outpatient treatment have been anonymously included on the registry. The following 7 countries participated in the register: Russian Federation, Republic of Armenia, Republic of Belarus, Republic of Kazakhstan, Kyrgyz Republic, Republic of Moldova, Republic of Uzbekistan. This closed multicenter register with two nonoverlapping branches (in- and outpatient branch) provides 6 visits: 3 in-person visits during the acute period and 3 telephone calls after 3, 6, 12 months. Subject recruitment lasted from June 29, 2020 to October 29, 2020. Register will end on October 29, 2022. A total of 9 fragmentary analyzes of the registry data are planned. This fragment of the study presents the results of the post-hospitalization period in COVID-19 survivors after 3 and 6 months.Results.According to the AKTIV register, patients after COVID-19 are characterized by long-term persistent symptoms and frequent seeking for unscheduled medical care, including rehospitalizations. The most common causes of unplanned medical care are uncontrolled hypertension (HTN) and chronic coronary artery disease (CAD) and/or decompensated type 2 diabetes (T2D). During 3- and 6-month follow-up after hospitalization, 5,6% and 6,4% of patients were diagnosed with other diseases, which were more often presented by HTN, T2D, and CAD. The mortality rate of patients in the post-hospitalization period was 1,9% in the first 3 months and 0,2% for 4-6 months. The highest mortality rate was observed in the first 3 months in the group of patients with class II-IV heart failure, as well as in patients with cardiovascular diseases and cancer. In the pattern of death causes in the post-hospitalization period, following cardiovascular causes prevailed (31,8%): acute coronary syndrome, stroke, acute heart failure.Conclusion.According to the AKTIV register, the health status of patients after COVID-19 in a serious challenge for healthcare system, which requires planning adequate health system capacity to provide care to patients with COVID-19 in both acute and post-hospitalization period.


  • Open Access

    Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)

    by E. I. Tarlovskaya, A. G. Arutyunov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, et al.

    Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry. Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients’ privacy (data of nasal and throat smears; antibody titer; typical CT imaging features). The register territory included 7 countries: the Russian Federation, the Republic of Armenia, the Republic of Belarus, the Republic of Kazakhstan, the Kyrgyz Republic, the Republic of Moldova, and the Republic of Uzbekistan. The registry design: a closed, multicenter registry with two nonoverlapping arms (outpatient arm and in-patient arm). The registry scheduled 6 visits, 3 in-person visits during the acute period and 3 virtual visits (telephone calls) at 3, 6, and 12 mos. Patient enrollment started on June 29, 2020 and was completed on October 29, 2020. The registry completion is scheduled for October 29, 2022. The registry ID: ClinicalTrials.gov: NCT04492384. In this fragment of the study of registry data, the work group analyzed the effect of therapy for comorbidities at baseline on severity and outcomes of the novel coronavirus infection. The study population included only the patients who took their medicines on a regular basis while the comparison population consisted of noncompliant patients (irregular drug intake or not taking drugs at all despite indications for the treatment). Results The analysis of the ACTIVE registry database included 5808 patients. The vast majority of patients with COVID-19 had comorbidities with prevalence of cardiovascular diseases. Medicines used for the treatment of COVID-19 comorbidities influenced the course of the infectious disease in different ways. A lower risk of fatal outcome was associated with the statin treatment in patients with ischemic heart disease (IHD); with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists and with beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation; with oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD; with oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM); and with long-acting insulins in patients with type 1 DM. A higher risk of fatal outcome was associated with the spironolactone treatment in patients with CHF and with inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD). Conclusion      In the epoch of COVID-19 pandemic, a lower risk of severe course of the coronavirus infection was observed for patients with chronic noninfectious comorbidities highly compliant with the base treatment of the comorbidity.